Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "operations"

1128 News Found

Utthunga partners with VindAir to advance smart solutions for pharma industry
Digitisation | February 13, 2025

Utthunga partners with VindAir to advance smart solutions for pharma industry

The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability


Zydus Lifesciences posts Q3 FY25 net profit higher at Rs 1,024 Cr
News | February 10, 2025

Zydus Lifesciences posts Q3 FY25 net profit higher at Rs 1,024 Cr

During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent


Wockhardt posts Q3 net profit at Rs. 20 Cr
News | February 10, 2025

Wockhardt posts Q3 net profit at Rs. 20 Cr

Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25


Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr
News | February 08, 2025

Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr

During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.


Pharmexcil appoints Bhavin Mukund Mehta as Vice Chairman
People | February 05, 2025

Pharmexcil appoints Bhavin Mukund Mehta as Vice Chairman

Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry


Carbogen Amcis appoints Stephan Fritschi as CEO
People | February 04, 2025

Carbogen Amcis appoints Stephan Fritschi as CEO

Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.


Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr
News | February 03, 2025

Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr

Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,


Biocon’s S&P Global ESG Score improves to 69 for 2024
Sustainability | January 30, 2025

Biocon’s S&P Global ESG Score improves to 69 for 2024

Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53


Piramal Pharma Q3 FY25 revenue up 13%
News | January 30, 2025

Piramal Pharma Q3 FY25 revenue up 13%

CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business


OneSource receives EIR with VAI classification from USFDA for BLD facility
Drug Approval | January 29, 2025

OneSource receives EIR with VAI classification from USFDA for BLD facility

OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies